Breast cancer chemo may speed up brain aging, new study suggests
NCT ID NCT02122107
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how chemotherapy and other factors affect thinking and memory in older women who survived breast cancer. Researchers will compare these women to older women who never had cancer. They will also study how genetics and smoking history play a role. About 500 women will take memory tests and surveys over two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
499 people
The number who actually took part.
- Started
-
Apr 2014
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
We propose to enroll 540 participants into the study across the 2 sites: 270 participants (approximately 180 patients and 90 controls) from MSK and 270 participants from City of Hope (approximately 180 patients, and 90 controls).
- Ages
-
60 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The neuropsychological assessments were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the tests. Friend nominated, non-cancer controls will be frequency matched on age (+/- 5 years), education (less than college vs. some college and above), and race will be recruited using the same eligibility criteria as survivors except for no history of cancer. For cancer patients, eligibility includes: * As per medical record or self-report, post-menopausal female * As per medical record or self-report, age 60 or older at recruitment * As per medical record or self-report, age 55 or older at the time of breast cancer diagnosis * As per medical record or self report, for cancers other than breast cancer or non-melanoma/basal cell skin cancer/squamous cell skin cancer: * Patient must be at least 3 years post diagnosis of that cancer * Not received chemotherapy treatment or external beam radiation for that cancer * As per medical record or self-report, 5-15 years post diagnosis of breast cancer at the time of enrollment * As per medical record or self-report, no evidence of any cancer disease * American Joint Committee on Cancer (AJCC) stages 0-III breast cancer survivor as per clinical judgment/electronic medical record (EMR) * Score of \< 11 on the Blessed Orientation-Memory-Concentration Test (BOMC) * In the judgment of the consenting professional, able to communicate well enough in English through verbal and written communication to complete the study assessments and provide informed consent * English proficiency verified through an adapted Bidimensional acculturation scale, score of 2.5 or above \*\*\*The scale will only be administered to participants who report also speaking a language other than English. For controls participants, eligibility includes: * As per medical record or self-report, post-menopausal female * As per medical record or self-report, age 60 and older at recruitment * In the judgment of the consenting professional, able to communicate well enough in English through verbal and written communication to complete the study assessments and provide informed consent °English proficiency verified through an adapted Bidimensional acculturation scale, score of 2.5 or above. \*\*\*The scale will only be administered to participants who report also speaking a language other than English. * Score of \< 11 on the Blessed Orientation-Memory-Concentration Test (BOMC) * As per self report, no history of treatment with chemotherapy * As per self report no history of cancer except non-melanoma/basal cell skin cancer squamous cell skin carcinoma Exclusion Criteria: * For cancer patients, exclusion criteria includes: * As per medical record or self report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g., Alzheimer's, Parkinson's, Multiple Sclerosis, dementia, seizure disorders, etc) * As per medical record or self report, history of stroke or head injury requiring visit to the emergency room or hospitalization * As per medical record or self report, diagnosis of major Axis I psychiatric disorder including schizophrenia, manic-depressive disorder, or substance use disorders * As per self report or in the judgment of the consenting professional, visual or auditory impairment that would preclude ability to complete assessments * As per self report or as confirmed by the medical record, if the patient is taking anti-depression or anti-anxiety medication, \< 2 months on these medication or a change in the prescribed dose in the past 2 months * Previously or actively participating in protocol MSK IRB# 10-079 * For control participants, exclusion criteria include * As per self report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g., Alzheimer's, Parkinson's, Multiple Sclerosis, dementia, seizure disorders, etc.) * As per self report, history of stroke or head injury requiring visit to the emergency room or hospitalization * As per self report, diagnosis of major Axis I psychiatric disorder including schizophrenia, manic-depressive disorder, or substance use disorder * As per self report, or in the judgment of the consenting professional, visual or auditory impairment that would preclude ability to complete assessments * As per self report,if the person is taking anti-anxiety or anit-depression medication \<2 months on these medications or a change in the prescribed dose in the past 2 months * Previously or actively participating in protocol 10-079
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?